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10.1126/sciadv.1601017Polymyxins and quinazolines are LSD1/KDM1A
inhibitors with unusual structural features
Valentina Speranzini,1* Dante Rotili,2 Giuseppe Ciossani,1 Simona Pilotto,1 Biagina Marrocco,1
Mariantonietta Forgione,2,3 Alessia Lucidi,2 Federico Forneris,1 Parinaz Mehdipour,4 Sameer Velankar,5
Antonello Mai,2,6† Andrea Mattevi1†Because of its involvement in the progression of several malignant tumors, the histone lysine-specific demethylase
1 (LSD1) has become a prominent drug target in modern medicinal chemistry research. We report on the discovery
of two classes of noncovalent inhibitors displaying unique structural features. The antibiotics polymyxins bind at
the entrance of the substrate cleft, where their highly charged cyclic moiety interacts with a cluster of positively
charged amino acids. The same site is occupied by quinazoline-based compounds, which were found to inhibit the
enzyme through a most peculiar mode because they form a pile of five to seven molecules that obstruct access
to the active center. These data significantly indicate unpredictable strategies for the development of epige-
netic inhibitors.INTRODUCTION
Lysine-specific demethylase 1 (LSD1/KDM1A) plays fundamental roles
in regulating gene expression through the removal of monomethyla-
tion and dimethylation marks from Lys4 of histone H3. Its deregula-
tion is frequently observed in human solid cancers and leukemia (1).
A large and constantly increasing number of LSD1 inhibition studies
are available and use in silico, in vitro, and high-throughput approaches
to identify different classes of compounds that could specifically target
demethylation activity (2, 3). Various inhibitors have been identified
but, nevertheless, the most successful strategy still relies on the se-
quence and structure similarity of LSD1 to monoamine oxidases A
and B, which are well-exploited drug discovery targets (4). In par-
ticular, tranylcypromine derivatives, originally developed as covalent
inhibitors of monoamine oxidases, remain the best-studied class of
specific LSD1 inhibitors and have reached clinical stages. They cova-
lently bind the flavin adenine dinucleotide (FAD) cofactor and, there-
fore, completely abolish demethylation activity (5). Given the complex
biological functions of the enzyme and its involvement in a variety of
macromolecular complexes targeting chromatin, the identification of
highly specific, reversible LSD1 drug-like inhibitors and druggable
sites beyond the region near the flavin at the core of a catalytic site
remains an open challenge.
LSD1-CoRESt (RE1-silencing transcription factor co-repressor)
features an open cleft that is enriched in negatively charged amino
acids and forms the binding site for the H3 N-terminal residues. The
histone tail binds in a folded conformation, which enables the estab-
lishment of specific interactions with the surrounding enzyme residuesand positions methyl-Lys4 in proximity to the flavin (6, 7). Inspired
by this knowledge, out of a rather large collection of compounds
available in our laboratories (about 2000, including small mole-
cules, natural compounds, and known drugs), we selected a subset
of potential ligands with positively charged groups (for example,
amines). The compounds were first probed by thermal shift assay
using ThermoFAD (8). Promising candidates were then evaluated
by established in vitro LSD1 activity assays (9). Such a relatively sim-
ple strategy uncovered two new classes of LSD1 inhibitors (Fig. 1),
which reveal unexpected binding modes at the same protein surface,
establishing specific and common contacts, and highlight novel routes
for the development of compounds targeting epigenetic processes.RESULTS AND DISCUSSION
Polymyxins inhibit LSD1 by binding at the rim of the
active-site cleft
The first hits that we identified were polymyxin B and polymyxin E
(also known as colistin)—well-known antibiotics used against multidrug-
resistant bacteria, such as carbapenemase-producing Enterobacteriaceae
or Pseudomonas aeruginosa (10). These compounds are natural cyclic
peptides with a linear head group and contain five positively charged
propanamine units. Polymyxins B and E differ in terms of hydrophobic
side chain (Phe in polymyxin B and Leu in polymyxin E) and an extra
methyl in the head group of polymyxin B (Fig. 1A). The magnitude of
their binding was immediately evident because they induced a 6°C
increase in the melting temperature (Tm) of LSD1-CoREST. Enzymatic
assays consistently indicated that both compounds compete against
the substrate histone H3 peptide (methylated on Lys4) to inhibit
LSD1-CoREST with Ki values of (157 to 193) ± (26 to 38) nM; fluo-
rescence polarization experiments fully confirmed this degree of af-
finity. These data clearly demonstrated that these antibiotics form a
new class of LSD1-CoREST inhibitors. Therefore, we tested polymyxin
E (colistin) in cultured leukemia cells (MV4-11) to probe its ability to
inhibit LSD1 in a cellular context (11). The inhibitor was used at con-
centrations comparable to the ones used for antibiotic administration1 of 8
R E S EARCH ART I C L Ein septic patients (about 1 mM; fig. S1) (12). No remarkable effects on
either cell growth or H3-Lys4/H3-Lys9 methylation (either globally or
at a specific LSD1 target gene) were observed. It is possible that the
compound does not cross the plasma membrane (as is typical of pep-
tides), limiting its cellular efficacy, but we cannot rule out that LSD1
inhibition may, in the long term, contribute to the toxicity observed in
polymyxin-treated patients (13).
To elucidate the specific binding modes of the newly discovered
inhibitors, we determined the three-dimensional structures of LSD1-
CoREST in complex with both compounds (table S1). Over numerous
soaking and cocrystallization attempts using either polymyxin B or E,
the unbiased electron density maps always displayed large circular
peaks (tables S1 and S2 and fig. S2). Inside these maps, we could
model the macrocyclic region of the inhibitor, whereas the extended
linear aliphatic head group (not visible in the electron density) was
assigned zero occupancy during refinement and deposition of the finalSperanzini et al. Sci. Adv. 2016; 2 : e1601017 9 September 2016structural models (Fig. 2A). However, all collected data sets con-
sistently confirmed that these large antibiotics bind with their circular
peptide moieties at the entrance of the H3 tail-binding cleft (Fig. 2B).
Given the binding affinity for polymyxins and the high concentrations
used in the crystallographic experiments, we believe that the electron
density genuinely reflects the presence of multiple orientations during
binding. The circular nature of the ligands makes it plausible that
other “rotated” orientations may exist with lower occupancies. The
binding region is characterized by a set of negatively charged residues,
which we now find to form a high-affinity binding site for polymyxins
(Fig. 2C). In support of this notion, the affinity for these antibiotics is
10-fold decreased (Kd = 4.7 ± 0.7 mM for polymyxin B) in an LSD1
mutant carrying the Glu379Lys substitution (14), which reverses the
charge in one of the residues interacting with the inhibitor. In es-
sence, the circular polymyxins form a crown of positive charges that is
well suited to interact with the negatively charged entrance to the H3Fig. 1. Polymyxins and quinazolines bind LSD1-CoREST. (A) Chemical structures of polymyxin B and polymyxin E (colistin). Highlighted in blue
are the positively charged propanamine units. Both antibiotics bind LSD1-CoREST with high affinity, as observed by inhibition and binding assays.
(B) Chemical structures of quinazoline-derived compounds binding to LSD1. The atom numbering of the quinazoline core ring is shown for com-
pound E11 as a reference for the compound series. Fluorescence polarization (FP) signal was measured in millipolarization units (mP) and plotted
against inhibitor concentration. n.d., not determined.2 of 8
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(>5 Å) and do not bind deep in the catalytic region. This binding
mode found a remarkable counterpart in the second class of discov-
ered inhibitors.
Quinazoline derivatives designed as lysine mimics
inhibit LSD1-CoREST
Quinazoline-derived molecules were selected for our screening be-
cause they contain a dimethylaminopropanamine moiety that dec-
orates their core ring structure. These compounds were originally
synthesized as Lys-mimicking inhibitors of the histone H3K9 methyl-
transferases G9a and G9a-like protein (11, 15–17). In more detail, the
N-(1-benzylpiperidin-4-yl)-6,7-dimethoxy-2-(4-methyl-1,4-diazepan-Speranzini et al. Sci. Adv. 2016; 2 : e1601017 9 September 20161-yl)quinazolin-4-amine (BIX01294) was the first well-characterized
G9a inhibitor from which compound N4-(1-benzylpiperidin-4-yl)-N2-
(3-(dimethylamino)propyl)-6,7-dimethoxyquinazoline-2,4-diamine
(E11) and the very potent 2-cyclohexyl-N-(1-isopropylpiperidin-4-yl)-
6-methoxy-7-(3-(pyrrolidin-1-yl)propyl)quinazolin-4-amine (UNC0638)
were then developed [median inhibitory concentration (IC50) values of
1.7 mM (11), 0.778 mM (15), and <0.03 mM (17), respectively]. We also
probed the desmethoxy analog of E11, which is known to be a weaker in-
hibitor of G9a (the N4-(1-benzylpiperidin-4-yl)-N2-(3-(dimethylamino)
propyl)quinazoline-2,4-diamine (MC2694); IC50 = 41.9 mM; see the
Supplementary Materials). Thermal shift analysis indicated that these
compounds bind to LSD1-CoREST, with MC2694 and E11 yielding
large shifts (4° to 6°C) in the Tm of the enzyme. These preliminaryFig. 2. Polymyxins B and E bind LSD1 in a similar conformation in the active site. (A and B) When bound, the antibiotics do not establish
interactions with FAD (yellow sticks). Polymyxin B is depicted in blue sticks and polymyxin E is depicted in orange sticks. 2Fo − Fc electron density
maps (1.2s level) are calculated before the inclusion of the ligand in the refinement. (C) LSD1-bound polymyxins establish interactions with a patch
of negatively charged residues (highlighted in red on the protein surface).3 of 8
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ization assays, demonstrating that these quinazolines are high-affinity
ligands that competitively inhibit LSD1-CoREST. CompoundsMC2694
and E11 tightly bind the demethylase with Kd values in the range of
0.2 to 0.4 mM, whereas BIX01294 and UNC0638 are less potent with
a Kd of 2 to 9 mM. In summary, these molecules can be considered as
dual demethylase-methyltransferase inhibitors: E11 and BIX01294
show comparable inhibition against both enzymes, whereas MC2694
is >100-fold stronger against LSD1and UNC0638 is >100-fold stronger
against G9a.
A unique binding mode
We next determined the three-dimensional structure of LSD1-CoREST
in complex with E11, the most potent compound in the quinazoline
series (table S1). This study led to a most surprising observation: The
inhibitor occupies the same site of polymyxins and binds in a stacked
disposition, distant from the FAD cofactor and capping the entrance
of the active site with five inhibitor copies (with additional density
hinting at a sixth low-occupancy molecule) (Fig. 3). Moving gradually
away from the flavin, these multiple ligand copies showed increasing
solvent exposure and progressively limited interactions with the LSD1-
CoREST heterodimer. We performed several soaking experiments to
rule out crystallization artifacts attributable to ligand concentration,
which was tested from 0.8 to 5 mM. In all cases, the ligand acquiresSperanzini et al. Sci. Adv. 2016; 2 : e1601017 9 September 2016the same stacking conformation, with the same copy number and high-
ly flexible side chains exhibiting poorer electron density definition. The
molecules alternate their orientations, mixing “face-to-face” and “head-
to-tail” stacking modes (Fig. 3C). In this way, the molecular stack fully
obstructs the active-site cleft, inherently explaining the inhibitory activ-
ity exerted by these compounds. The unusual binding stoichiometry
was confirmed in solution by isothermal titration calorimetry. Two
types of binding sites for E11 were identified: A primary binding site
shows high affinity (Kd = 660 ± 260 nM) and 1:1 (N = 0.99 ± 0.07)
stoichiometry, whereas a secondary binding site features lower affinity
(Kd = 28 ± 11 mM) and ~7:1 (N = 7.1 ± 0.6) stoichiometry. The binding
affinities for the primary site measured by calorimetry, fluorescence po-
larization, and inhibition assays are highly similar (Fig. 1B and fig. S3).
Whether the stacks are preformed in solution or assemble upon sequen-
tial binding to the protein remains to be seen. Given all data in solution
and in crystallo, it is plausible that a first quinazoline molecule binds
with high affinity and specificity. The others then rapidly occupy the
site in a cooperative fashion, establishing protein-ligand and ligand-
ligand interactions.
Given this most unusual mode of binding, we produced and tested
other quinazoline analogs. Specifically, we probed the roles of the dif-
ferent substituents on the inhibitor ring to evaluate their roles in lig-
and stability, inhibition, and stacking binding mode. The removal of the
benzylpiperidine group at the quinazoline C-4 position negativelyFig. 3. Noncovalent quinazoline-derived compound E11 obstructs the LSD1 active site in a unique multiple stacking assembly. (A) A stack
of five inhibitor molecules (green sticks) binding the active site of LSD1-CoREST (white and wheat cartoon, respectively) at >5 Å from FAD (yellow
sticks). (B) Side view of the LSD1-CoREST complex with E11 showing the inhibitors at the entrance of the binding site. 2Fo − Fc electron density
maps (1.2s level) are calculated before the inclusion of the ligand in the refinement. I to V indicate each stacking inhibitor, with I being the most
proximal to FAD, and V the most distal. (C) Simplified views of inhibitor molecules stacking in alternate flipped orientations at an intermolecular
distance of 3.8 to 4.0 Å (side view). Red bars on the right indicate the position of the methoxy groups in each ligand. (D) Surface highlight (red) of
negatively charged residues of LSD1 that represent the primary binding region for compound E11.4 of 8
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LSD1 [N2-(3-(dimethylamino)propyl)-6,7-dimethoxy-N4,N4-
dimethylquinazoline-2,4-diamine (MC3767); Fig. 1B]. However,
we were able to solve the three-dimensional structure of the de-
methylase in complex with this compound, which retained the ca-
pability of stacking in multiple copies at the entrance of the LSD1 active
site (three visible copies; fig. S4). Removal of the disordered dimethyla-
minopropylamine branch at the C-2 position yielded more drastic effects,
completely abolishing inhibitor binding, as demonstrated by the lack of
thermal stabilization and enzyme inhibition [N-(1-benzylpiperidin-
4-yl)-2-chloro-6,7-dimethoxyquinazolin-4-amine (MC4120) and 2-
chloro-6,7-dimethoxy-N,N-dimethylquinazolin-4-amine (MC4121);
Fig. 1B]. In summary, the central quinazoline ring alone is not suffi-
cient to determine efficient inhibition and stable binding. To exert its
function, this molecular moiety has to be specifically decorated, in par-
ticular by short methoxy groups at the C-6 and C-7 positions (compare
E11 with MC2694; Fig. 1B) and by the lysine analog dimethylami-
nopropanamine at the C-2 position (compare E11 with MC4120).
The two most biochemically active compounds, E11 andMC2694,
were then tested in cultured leukemia cells (MV4-11) to probe their
ability to inhibit LSD1 in vivo. As a reference, we included benzyl (1-((4-(2-
aminocyclopropyl)phenyl)amino)-1-oxo-3-phenylpropan-2-yl)carbamate
(MC2580), a potent and well-characterized covalent LSD1 inhibitor (18).
The compounds displayed moderate effects on cell growth even after pro-
longed treatment at a concentration of 1 mM, which is above their mea-
sured Kd values (fig. S1A). Likewise, none of the LSD1 inhibitors showed
any effect on global H3-Lys4 and H3-Lys9 methylation levels, in agreement
with the previous characterization ofMC2580 (fig. S1B) (18). Conversely,
we did instead observe a more specific effect on LSD1 transcriptional ac-
tivity. Using quantitative reverse transcription polymerase chain reaction,
we analyzed the mRNA levels ofGfi1-B, a gene largely involved in hema-
topoiesis and previously demonstrated to be a target of LSD1 (19–21). As
illustrated in fig. S1C, 24 hours after treatment, the only compound that
strongly affected Gfi1-B expression was the reference covalent inhibitor
MC2580, but prolonged treatment with compound E11 led to a signif-
icant effect. Collectively, these data show that quinazoline compounds,
such as E11—though not as potent as the covalentMC2580 inhibitor—
are endowed with LSD1 inhibitory activity in the cellular context and can
be candidates for developing a potent class of noncovalent LSD1 inhibitors.
The unexpected binding mode of compounds E11 and MC3767
prompted us to perform a thorough research on the Protein Data Bank
(PDB) to explore whether such molecular arrangement was reported
in other protein-ligand structures. After application of an initial com-
putational filter on the basis of interatomic ligand distances and ligand
multiplicity, we identified 599 hits that were visually inspected for pos-
sible multicopy stacking interactions, reducing the total list of match-
ing candidates to 13 (fig. S5 and table S3). Among these, only two
structures showed a stacking assembly of more than two ligands: the
complex between troponin C and the antipsychotic drug trifluo-
perazine (PDB 1WRL and 1WRK) and the complex formed by the
binding of an acetylcholine-binding protein to an isoquinoline derivative
(PDB 4BFQ) (22). These crystal structures display average ligand stacking
distances of 3.9 ± 0.2 and 3.6 ± 0.2 Å, respectively, which are similar to
the distance of 3.9 ± 0.2 Å measured for E11. Intriguingly, there were
no hits showing five or more copies of the same molecule adopting a
stacked binding mode to inhibit their target, making our case unique.
p-Stacking interactions can be a successful strategy to increase
the potency of drugs targeting viral proteins that bind nucleic acidsSperanzini et al. Sci. Adv. 2016; 2 : e1601017 9 September 2016(23, 24). Our data reveal the potential for the use of similar approaches
to designing potent inhibitors for nonviral targets as well. In this con-
text, a truly fascinating observation emerges from our studies: Similar
or identical inhibitors can have utterly different binding modes,
depending on the target. The quinazoline inhibitors do bind to G9a
histone methyltransferase as “single molecules” rather than as a multi-
molecular stack, which is uniquely found in LSD1 (fig. S6) (15). This
implies that stacking does not simply reflect an intrinsic property of
the quinazoline scaffold but rather arises from the architecture of the
binding site that promotes this type of interaction.
An expanded druggable surface for chemically and
functionally diverse inhibitors
The rationale for selecting candidate compounds was their poten-
tial ability to mimic the dimethyl Lys4 moiety of the H3 tail substrate
bound in direct contact with the flavin, in the deepest and narrowest
part of the catalytic center (6, 25). Our screening led to the discovery
of new inhibitor classes that, though chemically unrelated, both bind at
the rim of the active site. This highly charged region was previously in-
dicated as a candidate for the design of nonreversible inhibitors (26).
We could now identify a protein surface area for ligand binding larger
than that previously exploited in inhibition studies, as observed by com-
paring the hereby reported inhibitor complexes with all LSD1 structures
bound to peptide ligands and covalent inhibitors (fig. S7 and table S4).
The outer and more accessible location makes it particularly attractive
for inhibitors that not only block Lys4 demethylase activity per se but
also impair binding to LSD1-CoREST interactors.
Polymyxins have serious side effects that limit their usage to in-
fections that cannot be otherwise treated. Nevertheless, our findings
highlight them as possible drugs to be repurposed for simultaneous tar-
geting epigenetic processes and bacterial infections, for instance, in
the context of leukemia. It is fascinating to see how the chemical
complexity of natural compounds, such as polymyxins, can exert mul-
tiple effects ranging from epigenetic enzyme inhibition to disruption
of Gram-negative bacterial membranes. At the same time, our data also
demonstrate that a seemingly simple moiety, such as the quinazoline
core, can represent a privileged scaffold for developing inhibitors that
target epigenetic enzymes. Finely tuned decorations of the core ring
structure may provide the appropriate selectivity for the desired target
proteins, potentially enabling the design of multitarget compounds
that impair the dynamics of demethylation and methylation cycles.MATERIALS AND METHODS
Chemicals
Polymyxin B and polymyxin E (colistin) were purchased as sulfate
salts from Sigma-Aldrich. Syntheses of E11, MC2694, MC3767,
MC4120, and MC4121 are reported in the Supplementary Materials
and Methods.
Inhibition and binding assays
Protein expression in Escherichia coli and copurification of LSD1D124-
CoREST1D305 (LSD1-CoREST) were performed using previously de-
scribed procedures (6). Thermal stability, activity on histone H3K4me
peptide, and inhibition of human LSD1-CoREST were measured using
established protocols (6, 8). Fluorescence polarization experiments were
performed on a CLARIOstar plate reader (BMG LABTECH) in a 384-5 of 8
R E S EARCH ART I C L Ewell format using previously described protocols (7). Direct binding of
the histone H3 N-terminal tail peptide to LSD1-CoREST was assayed
using protein samples (final concentration, 2 mM) with labeled peptides
(constant at a final concentration of 1 nM) followed by serial 1:1 dilu-
tions. For competitive experiments, each well contained LSD1-CoREST
(constant at a final concentration of 60 nM) and labeled peptides (fixed
at a final concentration of 1 nM) to which decreasing concentrations of
the competing inhibitors were added: 0 to 200 mM for MC3767,
BIX01294, UNC0638, MC4120, and MC4121, and 0 to 50 mM for
polymyxins, E11, and MC2694. Given the complexity of the system,
including the possibility that the stack does not comprise a fixed num-
ber of molecules, we refrained frommodifying the standard mathemat-
ical models that are used in affinity data analysis and processing (7).
Isothermal titration calorimetry
Experiments were performed at 25°C using a MicroCal iTC200 calo-
rimeter in LSD1-CoREST storage buffer [25 mM KH2PO4 (pH 7.2)
and 5% glycerol] with 21.1 mM LSD1-CoREST and 1.5 mM E11. Data
were corrected for heat of dilution and fitted with the Origin 7.0 soft-
ware package (MicroCal).
Crystallization, data collection, and refinement
LSD1-CoREST crystals were prepared at 20°C in 100 mM N-(2-
acetamido)iminodiacetic acid (pH 6.5) and 1.2 M Na/K tartrate using
the hanging-drop technique. Soaking was performed by incubating
crystals with 0.8 to 5 mM compounds for 1 to 48 hours at 20°C; this
was followed by washing in a reservoir solution supplemented with
20% glycerol for cryoprotection and immediate freezing in liquid ni-
trogen. X-ray diffraction data were collected at a wavelength of 1.000 Å
on beamlines X06SA and X06DA at the Swiss Light Source (SLS; Villigen,
Switzerland) and at a wavelength of 0.976 Å on beamline ID23EH1
at the European Synchrotron Radiation Facility (ESRF; Grenoble,
France). Data processing and scaling were carried out using MOSFLM
(27), XDS (28), and AIMLESS (29). The structures were solved by mo-
lecular replacement using PHASER (30). Structure refinement was
performed using REFMAC5 (31) and phenix.refine (32). Topologies
for the inhibitors were obtained from the PRODRG server (33). For
polymyxins B and E, initial ligand-free electron density maps were
subjected to multiple cycles of solvent flattening density modification
using PARROT (29) and calculation of feature-enhanced maps using
phenix.fem (34), enabling the identification of the macrocycle ring
electron density in all data sets (fig. S2). Ligand atoms that could not
be identified in the electron density were assigned zero occupancy in the
final deposited models. MolProbity (35) and the PDB validation tools
(36) were used for structure validation. All structures had less than 0.1%
Ramachandran outliers and ~95% of residues in the favorable regions of
the Ramachandran plot. Final data collection and refinement statistics
are shown in tables S1 and S2. Additional data sets for polymyxins were
deposited as open data archive. Structural figures were prepared using
PyMOL (The PyMOL Molecular Graphics System; Schrödinger LLC;
www.pymol.org).SUPPLEMENTARY MATERIALS
Supplementary material for this article is available at http://advances.sciencemag.org/cgi/
content/full/2/9/e1601017/DC1
Supplementary Materials and Methods
fig. S1. Cellular characterization of LSD1 reversible inhibitors.Speranzini et al. Sci. Adv. 2016; 2 : e1601017 9 September 2016fig. S2. Comparison of polymyxin B and polymyxin E conformations from multiple data sets.
fig. S3. Characterization of the binding of E11 to LSD1-CoREST in solution by isothermal
titration calorimetry.
fig. S4. Noncovalent quinazoline-derived compound MC3767 binds the LSD1 active site in a
multiple stacking assembly as E11.
fig. S5. Workflow of the PDB search for multicopy stacking small-molecule inhibitors.
fig. S6. Comparison of histone methyltransferase G9a-like protein (GLP) and histone
demethylase LSD1 in complex with compound E11.
fig. S7. LSD1 druggable space is expanded by the binding of noncovalent compounds.
table S1. Diffraction, data collection, and refinement statistics.
table S2. Diffraction, data collection, and refinement statistics for all data sets of polymyxins
B and E.
table S3. List of protein inhibitor structures displaying multiple stacking conformation identified
from PDB search.
table S4. List of published LSD1 PDB structures in complex with ligands.
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